1. Home
  2. WYY vs MNOV Comparison

WYY vs MNOV Comparison

Compare WYY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

N/A

Current Price

$7.77

Market Cap

122.3M

Sector

Technology

ML Signal

N/A

Logo Medicinova Inc

MNOV

Medicinova Inc

N/A

Current Price

$1.66

Market Cap

137.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WYY
MNOV
Founded
1991
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.3M
137.8M
IPO Year
2005
2004

Fundamental Metrics

Financial Performance
Metric
WYY
MNOV
Price
$7.77
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.25
AVG Volume (30 Days)
357.9K
★ 792.7K
Earning Date
08-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.01
N/A
Revenue
★ $150,545,364.00
$2,360,807.00
Revenue This Year
$12.26
$78.20
Revenue Next Year
$25.66
N/A
P/E Ratio
$746.23
★ N/A
Revenue Growth
5.59
★ 194.15
52 Week Low
$3.96
$1.17
52 Week High
$24.30
$3.90

Technical Indicators

Market Signals
Indicator
WYY
MNOV
Relative Strength Index (RSI) 39.77 40.69
Support Level $4.46 $1.28
Resistance Level $12.69 $3.90
Average True Range (ATR) 1.23 0.37
MACD -0.46 -0.14
Stochastic Oscillator 40.88 1.56

Price Performance

Historical Comparison
WYY
MNOV

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: